Search

Objective: To investigate the relationship between serum annexin (ANX) A2, ANXA3 and the efficacy of chemotherapy in patients with metastatic colorectal cancer (mCRC). Methods: 90 mCRC patients who were admitted to the Affiliated Hospital of Xuzhou Medical University from January 2019 to October 2020 were selected, patients were divided into non-remission group and remission group according to the efficacy of mFOLFOX6 chemotherapy combined with cetuximab. Serum ANXA2 and ANXA3 levels were detected by enzyme-linked immunosorbent assay. Using univariate, multivariate logistic regression analysis, and receiver operating characteristic (ROC) curve analysis, respectively, the influencing factors of unresponsive chemotherapy in mCRC patients and the predictive value of serum ANXA2 and ANXA3 on unresponsive chemotherapy in mCRC patients. Results: The objective remission rate of 90 mCRC patients was 58.89% (53/90). Univariate analysis showed that statistical differences between the two groups in terms of age, ileocecal tumor, TNM stage, Zubrod-Eastern Tumor Assistance Group-World Health Organization score (ZPS), treatment goal, ANXA2 and ANXA3 (P<0.05). Multivariate Logistic regression analysis showed that, ileocecal tumor, TNM stage IV, ZPS score 1-2 and increased ANXA2 and ANXA3 were independent risk factors of non-remission in mCRC patients (P<0.05). The ROC curve analysis showed that the area under the curve (AUC) predicted by serum ANXA2 was 0.787. The ROC curve analysis showed that the AUC that predicted by ANXA3 was 0.791, and that predicted by serum ANXA2 and ANXA3 was 0.904. The AUC predicted by serum ANXA2 and ANXA3 was the largest (P<0.05). Conclusion: Increase serum ANXA2 and ANXA3 levels are independent risk factors of chemotherapy non-remission in mCRC patients, which can affect the efficacy of chemotherapy in mCRC patients, and combination of the two has a higher value in predicting chemotherapy non-remission in mCRC patients. [ABSTRACT FROM AUTHOR]

Objective: To study the relationship between serum cancer antigen 125 (CA125), insulin growth factor 1 (IGF1), Annexin A3, human epididymal protein 4 (HE4) and carboplatin resistance and prognosis in patients with epithelial ovarian cancer (EOC). Methods: 100 patients with EOC who were admitted to Central Theater General Hospital from April 2015 to April 2018 were selected, all patients were treated with carboplatin based chemotherapy. They were divided into drug-resistant group with 25 cases and non drug-resistant group with 75 cases according to whether there was carboplatin resistance. The levels of serum CA125, IGF1, Annexin A3 and HE4 in the two groups were detected and compared. The baseline data of the two groups were compared. The influencing factors of carboplatin resistance in patients with EOC were analyzed by multivariate Logistic regression. In addition, all patients were followed up for 3 years. According to the difference of prognosis, they were divided into 49 cases in the death group and 51 cases in the survival group. Results: The levels of serum CA125, IGF1, Annexin A3 and HE4 were compared between the two groups. The levels of serum CA125, IGF1, Annexin A3 and HE4 in drug-resistant group were higher than those in non drug-resistant group (P＜0.05). The proportion of FIGO stage Ⅲ ~ Ⅳ stage in drug-resistant group was higher than that in non drug-resistant group (P＜0.05). Multivariate Logistic regression analysis showed that the high levels of serum CA125, IGF1, Annexin A3 and HE4 and FIGO stage Ⅲ ~ Ⅳ were the risk factors of carboplatin resistance in patients with EOC (P＜0.05). The levels of serum CA125, IGF1, Annexin A3 and HE4 in the death group were higher than those in the survival group (P＜0.05). Conclusion: The elevated levels of serum CA125, IGF1, Annexin A3 and HE4 are the influencing factors of carboplatin resistance in patients with EOC, and which may be related to the poor prognosis of patients with EOC. [ABSTRACT FROM AUTHOR]